CD8A and neoplasm: Recent studies have reported multiple ongoing clinical trials combining epigenetic therapies with immunotherapies, such as HDAC inhibitors, DNMT inhibitors, LSD1 inhibitors and EZH2 inhibitors which could lead to more potent CD8+ T cell anti-tumor immune responses.